Full Text | PDF

Int J Biol Sci 2023; 19(14):4689-4708. doi:10.7150/ijbs.80017 This issue Cite

Research Paper

Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response

Hong Zheng^1,2#, Minghao Wang^1,3#, Shiyu Zhang¹, Dongxue Hu¹, Qiaoyun Yang¹, Ming Chen⁴, Xia Zhang⁵, Yi Zhang^3✉, Jigang Dai^2✉, Yih-Cherng Liou^1✉

1. Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore.
2. Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, China.
3. Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China.
4. Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
5. Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China.
#Hong Zheng and Minghao Wang contributed equally to this work.

✉ Corresponding authors: Yih-Cherng Liou, Department of Biological Sciences, Faculty of Science National University of Singapore (NUS), National University of Singapore, Singapore, Singapore. Email: dbslycedu.sg. Jigang Dai, Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, China. Email: daijigangedu.cn. Yi Zhang, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China. Email: zhangyi1489com. More

Abstract

Nucleolar and spindle-associated protein 1 (NUSAP1) is a microtubule-associated protein that plays a crucial role in mitosis. Despite initial reports suggesting a potential involvement of NUSAP1 in tumor progression and malignant cell regulation, there has been no systematic analysis of its role in the tumor immune microenvironment, nor its predictive value for prognosis and immunotherapy response across different cancer types. In this study, we analyze NUSAP1 mRNA and protein expression levels in various human normal and tumor tissues, using data from TCGA, GTEx, CPTAC, HPA databases, and clinical samples. Our findings reveal that NUSAP1 is highly expressed in multiple tumor tissues across most cancer types and is primarily expressed in malignant and immune cells, according to single-cell sequencing data from the TISCH database. Prognostic analysis based on curated survival data from the TCGA database indicates that NUSAP1 expression levels can predict clinical outcomes for 26 cancer types. Furthermore, Gene Set Enrichment Analysis (GSEA) suggests that NUSAP1 promotes cell proliferation, tumor cell invasion, and regulation of anti-tumor response. Analysis of immune score, immune cell infiltration, and anti-cancer immunity cycle using ESTIMATE, TIMER, and TIP databases show that high NUSAP1 levels are associated with low CD4⁺T and NKT cell infiltration but high Th2 and MDSC infiltration, inversely correlated with antigen-presenting molecules and positively correlated with a variety of immune negative regulatory molecules. Notably, patients with melanoma, lung, and kidney cancer with high NUSAP1 expression levels have shorter survival times and lower immunotherapy response rates. Using Cmap analysis, we identify Entinostat and AACOCF3 as potential inhibitors of NUSAP1-mediated pro-oncogenic effects. In vitro and in vivo experiments further confirm that NUSAP1 knockdown significantly reduces the proliferation ability of A549 and MCF-7 cells. Overall, our study highlights the potential of NUSAP1 expression as a novel biomarker for predicting prognosis and immuno-therapeutic efficacy across different human cancers and suggests its potential for developing novel antitumor drugs or improving immunotherapy.

Keywords: NUSAP1, pan-cancer, biomarker, prognosis, immunotherapy.

Citation styles

©2024 Ivyspring International Publisher. Terms of use